BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...Matthew Walsh as CFO and Rachel Stahler as chief information officer of its planned spinout Organon...
...to complete the spin out of its women’s health business, legacy brands and biosimilars into Organon...
BioCentury | Mar 10, 2014
Finance

The thesis on Thesan

...and CSO of pain company Kadmus Pharmaceuticals Inc. , which sold its key assets to Organon...
BioCentury | Sep 30, 2013
Clinical News

Bridion sugammadex regulatory update

...its 2009 acquisition of Schering-Plough Corp. Schering-Plough gained the compound through its 2007 acquisition of Organon...
BioCentury | Jul 22, 2013
Clinical News

Bridion sugammadex regulatory update

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon...
BioCentury | May 13, 2013
Clinical News

Bridion sugammadex regulatory update

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon...
BioCentury | Apr 15, 2013
Company News

Incyte Pharmaceuticals Inc., NV Organon deal

...sequence and expression database and LifeSeq GeneAlbum reagent set in exchange for annual access fees. Organon...
...collaboration. INCY is eligible to receive royalties. Incyte Pharmaceuticals Inc. (INCY), Palo Alto, Calif. NV Organon...
BioCentury | Dec 20, 2012
Strategy

MRC Technology extends reach

...for milestones and royalties. Organon has all rights to develop and commercialize the humanized antibody. Organon...
BioCentury | Nov 5, 2012
Clinical News

Bridion sugammadex: Phase III completed

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon...
BioCentury | Apr 18, 2011
Company News

Merck pharmaceuticals news

...Merck's Organon N.V. subsidiary proposed to restructure and reduce headcount of R&D at Dutch sites Oss...
...reduce headcount of R&D at Dutch sites Oss and Schaijk by 551 (53%) to 479. Organon...
BioCentury | Feb 21, 2011
Strategy

BioMarin wants control

...In an update last week, the pharma said it has been unable to sell its MSD-Organon...
...Merck said only the R&D portion of the facilities would be closed or divested. Of MSD-Organon's...
...internally, which could include the creation of a small R&D center of excellence at the Organon...
Items per page:
1 - 10 of 361
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...Matthew Walsh as CFO and Rachel Stahler as chief information officer of its planned spinout Organon...
...to complete the spin out of its women’s health business, legacy brands and biosimilars into Organon...
BioCentury | Mar 10, 2014
Finance

The thesis on Thesan

...and CSO of pain company Kadmus Pharmaceuticals Inc. , which sold its key assets to Organon...
BioCentury | Sep 30, 2013
Clinical News

Bridion sugammadex regulatory update

...its 2009 acquisition of Schering-Plough Corp. Schering-Plough gained the compound through its 2007 acquisition of Organon...
BioCentury | Jul 22, 2013
Clinical News

Bridion sugammadex regulatory update

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon...
BioCentury | May 13, 2013
Clinical News

Bridion sugammadex regulatory update

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon...
BioCentury | Apr 15, 2013
Company News

Incyte Pharmaceuticals Inc., NV Organon deal

...sequence and expression database and LifeSeq GeneAlbum reagent set in exchange for annual access fees. Organon...
...collaboration. INCY is eligible to receive royalties. Incyte Pharmaceuticals Inc. (INCY), Palo Alto, Calif. NV Organon...
BioCentury | Dec 20, 2012
Strategy

MRC Technology extends reach

...for milestones and royalties. Organon has all rights to develop and commercialize the humanized antibody. Organon...
BioCentury | Nov 5, 2012
Clinical News

Bridion sugammadex: Phase III completed

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon...
BioCentury | Apr 18, 2011
Company News

Merck pharmaceuticals news

...Merck's Organon N.V. subsidiary proposed to restructure and reduce headcount of R&D at Dutch sites Oss...
...reduce headcount of R&D at Dutch sites Oss and Schaijk by 551 (53%) to 479. Organon...
BioCentury | Feb 21, 2011
Strategy

BioMarin wants control

...In an update last week, the pharma said it has been unable to sell its MSD-Organon...
...Merck said only the R&D portion of the facilities would be closed or divested. Of MSD-Organon's...
...internally, which could include the creation of a small R&D center of excellence at the Organon...
Items per page:
1 - 10 of 361